Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

63 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A randomized, placebo controlled, multicenter study to evaluate the safety and efficacy of rofecoxib in the treatment of chronic nonbacterial prostatitis.
Nickel JC, Pontari M, Moon T, Gittelman M, Malek G, Farrington J, Pearson J, Krupa D, Bach M, Drisko J; Rofecoxib Prostatitis Investigator Team. Nickel JC, et al. Among authors: drisko j. J Urol. 2003 Apr;169(4):1401-5. doi: 10.1097/01.ju.0000054983.45096.16. J Urol. 2003. PMID: 12629372 Clinical Trial.
Sustained decrease in incidence of acute urinary retention and surgery with finasteride for 6 years in men with benign prostatic hyperplasia.
Roehrborn CG, Bruskewitz R, Nickel JC, McConnell JD, Saltzman B, Gittelman MC, Malek GH, Gottesman JE, Suryawanshi S, Drisko J, Meehan A, Waldstreicher J; Proscar Long-Term Efficacy and Safety Study Group. Roehrborn CG, et al. Among authors: drisko j. J Urol. 2004 Mar;171(3):1194-8. doi: 10.1097/01.ju.0000112918.74410.94. J Urol. 2004. PMID: 14767299 Clinical Trial.
Administration of a nonpeptidyl growth hormone secretagogue, L-163, 255, changes somatostatin pattern, but has no effect on patterns of growth hormone-releasing factor in the hypophyseal-portal circulation of the conscious pig.
Drisko JE, Faidley TD, Zhang D, McDonald TJ, Nicolich S, Hora DF, Cunningham P, Li C, Rickes E, McNamara L, Chang C, Smith RG, Hickey GJ. Drisko JE, et al. Proc Soc Exp Biol Med. 1999 Oct;222(1):70-7. doi: 10.1111/j.1525-1373.1999.09997.x. Proc Soc Exp Biol Med. 1999. PMID: 10510248
Transorbital approach to the porcine pituitary.
Drisko JE, Faidley TD, Hora DF Jr, Niebauer GW, Feeney WP, Friscino BH, Hickey GJ. Drisko JE, et al. J Invest Surg. 1996 Jul-Aug;9(4):305-11. doi: 10.3109/08941939609012480. J Invest Surg. 1996. PMID: 8887068
A potent, nonpeptidyl 1H-quinolone antagonist for the gonadotropin-releasing hormone receptor.
DeVita RJ, Walsh TF, Young JR, Jiang J, Ujjainwalla F, Toupence RB, Parikh M, Huang SX, Fair JA, Goulet MT, Wyvratt MJ, Lo JL, Ren N, Yudkovitz JB, Yang YT, Cheng K, Cui J, Mount G, Rohrer SP, Schaeffer JM, Rhodes L, Drisko JE, McGowan E, MacIntyre DE, Vincent S, Carlin JR, Cameron J, Smith RG. DeVita RJ, et al. Among authors: drisko je. J Med Chem. 2001 Mar 15;44(6):917-22. doi: 10.1021/jm000275p. J Med Chem. 2001. PMID: 11300873
Design and pharmacology of N-[(3R)-1,2,3,4-tetrahydroisoquinolinium- 3-ylcarbonyl]-(1R)-1-(4-chlorobenzyl)- 2-[4-cyclohexyl-4-(1H-1,2,4-triazol- 1-ylmethyl)piperidin-1-yl]-2-oxoethylamine (1), a potent, selective, melanocortin subtype-4 receptor agonist.
Sebhat IK, Martin WJ, Ye Z, Barakat K, Mosley RT, Johnston DB, Bakshi R, Palucki B, Weinberg DH, MacNeil T, Kalyani RN, Tang R, Stearns RA, Miller RR, Tamvakopoulos C, Strack AM, McGowan E, Cashen DE, Drisko JE, Hom GJ, Howard AD, MacIntyre DE, van der Ploeg LH, Patchett AA, Nargund RP. Sebhat IK, et al. Among authors: drisko je. J Med Chem. 2002 Oct 10;45(21):4589-93. doi: 10.1021/jm025539h. J Med Chem. 2002. PMID: 12361385
63 results